Low-grade malignant gliomas (LGG) are a heterogeneous group of cancers and the largest group of brain and spinal cord cancers, accounting for 40 to 50% of the total.
Most patients with a low-grade malignant glioma have a very good chance of survival (the 10-year survival rate is over 90%). The chance of a cure, however, depends to a significant degree on the subgroup and location of the cancer. Surgery is the therapy of choice, but it is not always possible depending on the location. More than one third of individuals in whom it is not possible to remove the cancer completely by surgery require further treatment, and some patients experience several recurrences, requiring therapy several times. The aim of LOGGIC Core is to improve understanding of the tumour biology of these cancers and to develop more individual approaches to therapy on this basis. About 20 children and adolescents are affected by this disease in Switzerland every year and can participate in the LOGGIC Core research project.
LOGGIC Core seeks to find out more about the tumour biology of low-grade brain cancers in children. State-of-the-art techniques are used to obtain a “fingerprint” of each tumour. The intention is to use all the molecular and clinical data compiled during the study to develop treatment strategies for future patients that are more specific to the individual patient. These findings are already being used to provide more individual treatment and in new therapy trials. This knowledge will be expanded further by LOGGIC Core.
The Hopp Kindertumorzentrum in Heidelberg and the Deutsche Krebsforschungszentrum in Germany are responsible for the international implementation of the study as sponsor. The Swiss Paediatric Oncology Group (SPOG) is responsible for performing the study in Switzerland (sponsor representative).
In short
-
This research project aims to find out more about low-grade malignant gliomas (LGG), a heterogeneous group of brain and spinal cord cancers.
-
At the time of diagnosis, it is not yet possible to identify those patients who are cured by surgery on its own and those who subsequently require several treatments.
-
This research project is collecting and analysing samples and data from patients in order to gain a better understanding of the disease and use that knowledge to develop more individualised therapeutic approaches. This can improve the treatment for patients in the long term.
Study team
National Study Chair
Prof. Dr. med. Katrin Scheinemann, M.Sc.
Director of the Haematology/Oncology Centre
Eastern Switzerland Children's Hospital Foundation
Vice National Study Chair
Prof. Dr. med. Ana Guerreiro Stücklin, MD PhD
Attending Physician in Neuro-oncology and Head of Research Group, Oncology Department
University Children's Hospital Zurich
Clinical Project Manager
Lara Fux
Teamleader Clinical Project Management
SPOG Coordinating Centre
+41 31 508 42 27
E-Mail
